Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

FDA approves ocular antiinflammatory agent

March 11, 1998

Preliminary results reported from phase II trials of Vitrase

March 6, 1998

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Feb. 25, 1998

Allergan's new antiglaucoma agents

Feb. 20, 1998

Genetic basis for RP described

Feb. 5, 1998

FDA issues approvable letter for BioLon

Feb. 4, 1998

Novo Nordisk discloses peripheral muscarinic cholinergic agonists

Jan. 13, 1998

NIH contemplates licensing ophthalmic technology to GenVec

Jan. 7, 1998

Alcon discloses new antiglaucoma agents in patent literature

Jan. 2, 1998

Medarex's secondary cataract product enters phase III

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...